SureTrader
Home > Boards > US Listed > Medical - Drugs > Momenta Pharmaceuticals, Inc. (MNTA)

MOMENTA PHARMACEUTICALS, INC. v. AMPHASTAR PHARMACEUTICALS, INC.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
floblu14 Member Profile
Member Level 
Followed By 19
Posts 2,446
Boards Moderated 0
Alias Born 07/20/06
160x600 placeholder
Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2015 Financial Results Conference Call and Webcast "GlobeNewswire Inc." - 2/5/2016 8:00:00 AM
Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences "GlobeNewswire Inc." - 2/1/2016 8:00:00 AM
Amended Statement of Ownership (sc 13g/a) "Edgar (US Regulatory)" - 1/8/2016 5:14:34 PM
Momenta, Mylan to Jointly Develop Six Biosimilars "Dow Jones News" - 1/8/2016 9:50:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 1/8/2016 8:05:58 AM
Momenta Pharmaceuticals Announces Worldwide Collaboration With Mylan to Jointly Develop and Commercialize Six Biosimilar Prod... "GlobeNewswire Inc." - 1/8/2016 8:00:00 AM
Mylan Announces Worldwide Collaboration with Momenta to Jointly Develop and Commercialize Six Biosimilar Products "PR Newswire (US)" - 1/8/2016 8:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 1/5/2016 4:48:24 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 1/5/2016 1:37:04 PM
Initial Statement of Beneficial Ownership (3) "Edgar (US Regulatory)" - 1/5/2016 10:34:06 AM
Momenta Pharmaceuticals to Webcast Presentation at the 34th Annual J. P. Morgan Healthcare Conference "GlobeNewswire Inc." - 1/5/2016 8:00:00 AM
Momenta Resumes Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study "GlobeNewswire Inc." - 12/21/2015 8:00:00 AM
Baxalta and Momenta Announce M923, a Proposed HUMIRA (adalimumab) Biosimilar, Met Primary Endpoint in Pharmacokinetic Study "GlobeNewswire Inc." - 12/21/2015 6:45:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 12/14/2015 4:58:28 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/14/2015 4:01:43 PM
Initial Statement of Beneficial Ownership (3) "Edgar (US Regulatory)" - 12/14/2015 12:50:49 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 12/14/2015 11:17:34 AM
Amended Statement of Beneficial Ownership (sc 13d/a) "Edgar (US Regulatory)" - 12/8/2015 4:07:09 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/7/2015 4:15:33 PM
Momenta Pharmaceuticals Appoints Matthew P. Ottmer as Chief Operating Officer "GlobeNewswire Inc." - 12/7/2015 10:30:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 11/23/2015 3:15:37 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 11/23/2015 3:12:04 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 11/23/2015 3:07:31 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 11/23/2015 3:04:20 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 11/23/2015 3:01:30 PM
floblu14 Member Level  Wednesday, 12/07/11 09:36:20 AM
Re: None
Post # of 15271 
MOMENTA PHARMACEUTICALS, INC. v. AMPHASTAR PHARMACEUTICALS, INC.

MOMENTA PHARMACEUTICALS, INC., Plaintiff-Appellee, and
SANDOZ, INC., Plaintiff-Appellee,
v.
AMPHASTAR PHARMACEUTICALS, INC., INTERNATIONAL MEDICATION SYSTEMS, LTD., WATSON PHARMACEUTICALS, INC. and WATSON PHARMA, INC., Defendants-Appellants.

Nos. 2012-1062, 2012-xxxx, 2012-xxxx

United States Court of Appeals, Federal Circuit.


December 6, 2011.


This order is nonprecedential

ORDER

Upon consideration of the November 17, 2011 order expediting briefing on the merits of this appeal, the motions to consolidate this appeal with forthcoming appeals, the motion for leave to file a corrected opening brief, the motion for leave to file public and confidential versions of its reply in support of its motion to stay the injunction, and the motions to amend the official caption to add Watson Pharma, Inc.,

IT IS ORDERED THAT:
(1) Oral argument for the merits of the appeal is scheduled to be held at 10 a.m., January 24, 2012, in Courtroom 201. The parties shall notify the clerk in writing of the name of the counsel who will present oral argument no later than January 9, 2012.
(2) The motions to consolidate will be granted and the official caption will be amended to add the appeal numbers from the district court's November 23, 2011 order denying their motion to dissolve the injunction and the district court's December 2, 2011 order denying their emergency motion for relief from the injunction, when those new appeals are docketed by this court.
(3) The motions to reform the caption are granted. Watson Pharma, Inc. is added to the caption. The revised official caption is reflected above.

http://www.leagle.com/xmlResult.aspx?xmldoc=In%20FCO%2020111206163.xml&docbase=CSLWAR3-2007-CURR


SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist